Seres Therapeutics cuts Cambridge lease, issues stock
Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC to reduce facilities costs and primary restoration obligations at 200 Sidney Street in Cambridge.
Rhea-AI Filing Summary
Seres Therapeutics, Inc. entered into a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC to reduce facilities costs and primary restoration obligations at 200 Sidney Street in Cambridge. The company will surrender about 21,295 rentable sq ft and retain about 47,341 rentable sq ft, with the remaining lease term shortened from January 13, 2031 to December 31, 2026.
As consideration, Seres will increase a letter of credit by about $2.2 million to a total of about $3.6 million to be applied to rent and operating expenses, pay a deferred termination amount of $3.85 million by January 4, 2027, and issue 103,520 shares of common stock at $4.83 per share (total $500,001.60) under an existing Form S-3 shelf registration. The shares will be freely tradeable when issued; if their issuance-date market value is below $500,000, Seres must pay the landlord the cash difference.
Positive
- None.
Negative
- None.
Filing Explained
The
8-K Event Classification
Key Figures
Key Terms
Third Amendment to Lease and Termination Agreement regulatory
letter of credit financial
registration statement on Form S-3 regulatory
prospectus supplement regulatory
Nasdaq Global Select Market financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What lease changes did Seres Therapeutics (MCRB) disclose on July 31, 2026?
How much space is Seres Therapeutics (MCRB) giving up at 200 Sidney Street?
What financial obligations did Seres Therapeutics (MCRB) assume for the lease termination?
What are the key terms of the Seres Therapeutics (MCRB) stock issuance to the landlord?
AI-generated analysis. How Rhea-AI works. Not financial advice.